Source comparison
CJC-1295 no DAC & Ipamorelin Body Recomposition: Protocol Comparison
Conservative Research 100mcg 2x daily (morning, pre-sleep) 42–58% Lean mass gain detectable at 6–8 weeks; modest fat loss Suitable for initial tolerance assessment; lower risk of side effects but slower observable changes Standard Research 200mcg 68–84% Lean m
This comparison does not assign a generated winner or score.
- Conservative Research
- 100mcg
- 2x daily (morning, pre-sleep)
- 42–58%
- Lean mass gain detectable at 6–8 weeks; modest fat loss
- Suitable for initial tolerance assessment; lower risk of side effects but slower observable changes
- Standard Research
- 200mcg
- 68–84%
- Lean mass gain at 4–6 weeks; moderate fat reduction
- Most commonly studied dosing; balances efficacy and tolerability across published protocols
- Intensive Research
- 300mcg
- 3x daily (morning, post-training, pre-sleep)
- 92–118%
- Lean mass gain at 3–5 weeks; pronounced fat loss
- Higher GH amplitude; requires close monitoring for side effects (water retention, joint discomfort, numbness)
- Single Peptide (Ipamorelin only)
- .
- 3x daily
- 28–34%
- Minimal recomposition; primarily appetite modulation
- Demonstrates synergy requirement. GHRP alone lacks sustained IGF-1 elevation needed for tissue anabolism
- Single Peptide (CJC-1295 no DAC only)
- 2x daily
- 31–39%
- Weak recomposition; limited without acute GH pulse
- GHRH amplification requires a GH secretagogue trigger to produce meaningful GH output
- The table demonstrates dose-response relationships and the non-negotiable requirement for dual-peptide synergy. Protocols using either peptide in isolation produce IGF-1 elevations below the threshold required for observable body composition changes. CJC1295 Ipamorelin 5MG 5MG formulations from Real Peptides provide exact 1:1 dosing ratios that simplify protocol coordination. Each vial contains equimolar amounts of both peptides, eliminating the measurement errors that compromise many research outcomes.